Amanote Research
Register
Sign In
Osteoblast-Derived PTHrP Is a Potent Endogenous Bone Anabolic Agent That Modifies the Therapeutic Efficacy of Administered PTH 1-34
Journal of Clinical Investigation
- United States
doi 10.1172/jci24918
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Date
August 25, 2005
Authors
D. Miao
Publisher
American Society for Clinical Investigation
Related search
Silencing of Parathyroid Hormone (PTH) Receptor 1 in T Cells Blunts the Bone Anabolic Activity of PTH
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
Converting Parathyroid Hormone-Related Peptide (PTHrP) Into a Potent PTH-2 Receptor Agonist
Journal of Biological Chemistry
Biochemistry
Cell Biology
Molecular Biology
Down-Regulation of Human Osteoblast PTH/PTHrP Receptor mRNA in End-Stage Renal Failure
Kidney International
Nephrology
Endogenous Intact PTH Is Suppressed During Teriparatide (rhPTH 1-34) Administration in Postmenopausal Women With Established Osteoporosis
Endocrine Journal
Endocrinology
Metabolism
Diabetes
Multiple Mechanisms Are Involved in Inhibition of Osteoblast Differentiation by PTHrP and PTH in KS483 Cells
Journal of Bone and Mineral Research
Endocrinology
Orthopedics
Sports Medicine
Metabolism
Diabetes
Secreted Frizzled-Related Protein 4 Is a Potent Tumor-Derived Phosphaturic Agent
Journal of Clinical Investigation
Medicine
Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects
PLoS ONE
Multidisciplinary
Erratum To: Amylin(1–8) Is Devoid of Anabolic Activity in Bone
Calcified Tissue International
Endocrinology
Orthopedics
Sports Medicine
Metabolism
Diabetes
Parathyroid Hormone (PTH)/PTH-related Peptide Type 1 Receptor (PPR) Signaling in Osteocytes Regulates Anabolic and Catabolic Skeletal Responses to PTH
Journal of Biological Chemistry
Biochemistry
Cell Biology
Molecular Biology
